GlassScriptPhysician profile
Sheldine Edwards
NPI 1952603441
$3,539.74
in general payments reported to CMS, 2019-2025
30 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.94 · 2023: $562 · 2024: $891 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,505 · Entertainment: $14.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.71 |
| Entertainment | $14.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.92 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $423.87 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Gilead Sciences, INC. | $355.35 | 2024-2025 | Descovy, Biktarvy |
| Lilly USA, LLC | $298.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $286.89 | 2023-2025 | |
| Novo Nordisk INC | $261.58 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $226.95 | 2024-2025 | Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $194.62 | 2023-2025 | |
| Viiv Healthcare Company | $156.70 | 2024-2025 | Cabenuva, Apretude, Dovato |
| Exact Sciences Corporation | $131.48 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.86 | 2023-2025 | Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $82.80 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.79 | 2023-2024 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $55.31 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $41.84 | 2021-2025 | Wavewriter Alpha Prime 16 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.87 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.92 | 2025 | Caplyta |
| Corcept Therapeutics | $32.27 | 2025 | Korlym |
| Siemens Medical Solutions USA, INC. | $30.80 | 2025 | Immulite 1000 Immunoassay System |
| Otsuka America Pharmaceutical, INC. | $25.31 | 2025 | Rexulti |
| Alvogen INC | $22.56 | 2025 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $21.67 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $21.49 | 2024 | Delstrigo, Pifeltro |
| Alnylam Pharmaceuticals INC. | $18.21 | 2023 | |
| Invivyd INC | $18.17 | 2025 | Pemgarda |
| Takeda Pharmaceuticals U.S.A., INC. | $15.27 | 2025 | Trintellix |
| Nevro Corp. | $15.23 | 2024 | Senza |
| Idorsia Pharmaceuticals US INC | $14.72 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.12 | 2025 | Zoryve |
| Optos, INC. | $14.09 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldine Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.